Clinical trial

Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC

NCT04446117

Drugs and interventions used in this trial

5 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Mapped RxNorm record Cabozantinib Normalized identity: cabozantinibView linked drug · Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Atezolizumab Normalized identity: atezolizumabView linked drug · Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Abiraterone Acetate Normalized identity: abiraterone acetateView linked drug · Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Enzalutamide Normalized identity: enzalutamideView linked drug · Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Prednisone Normalized identity: prednisoneView linked drug · Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC

Design: INTERVENTIONAL · Status: ACTIVE NOT RECRUITING · Phase: PHASE3

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusACTIVE_NOT_RECRUITING

Study typeINTERVENTIONAL

Start date2020-10-19

PhasePHASE3

Conditions

Metastatic Prostate Cancerverified · MONDO: metastatic prostate carcinoma

Prostate Adenocarcinomaverified · MONDO: prostate adenocarcinoma

Interventions

CabozantinibDRUG · verified · RxNorm: cabozantinib

AtezolizumabDRUG · verified · RxNorm: atezolizumab

Abiraterone AcetateDRUG · verified · RxNorm: abiraterone acetate

EnzalutamideDRUG · verified · RxNorm: enzalutamide

PrednisoneDRUG · verified · RxNorm: prednisone

Sponsors & collaborators

Exelixislead sponsor

Roche-Genentechcollaborator

Takedacollaborator

Mapped research locations

MadridSpain5 SeoulSouth Korea4 BarcelonaSpain4 BudapestHungary4 HoustonTexas, United States3 PragueCzechia3 SingaporeSingapore3 MilanItaly2 New HavenConnecticut, United States2 Saint PetersburgRussia2 ToulouseFrance2 StrasbourgFrance2

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT04446117 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.